Pulmonary Vascular Disease Clinical Trials

As a patient at Cedars-Sinai, you will have access to the latest clinical trials and research for pulmonary vascular disease. Backed by a respected team of specialists and researchers, our clinical trials aim to further the advancement of diagnosing and treating your condition.

Questions? See the Clinical Trials FAQs.

Condition:

Idiopathic, heritable, connective tissue disease-associated and HIV-associated pulmonary arterial hypertension

Participant Requirements:

  • Confirmed clinical diagnosis of IPAH, HPAH, PAH-CTD, PAH-HIV
  • NYHA Functional Class: II or III
  • 18-75 years old

Summary:

This study focuses on patients with pulmonary arterial hypertension (PAH) from the following subgroups: idiopathic PAH (IPAH), heritable PAH (HPAH), PAH associated with connective tissue disease (PAH-CTD) and PAH associated with HIV (PAH-HIV). The study is designed to evaluate the investigational use of a biologic product called CAP-1002. CAP-1002 consists largely of heart stem cells ("CDCs") grown from donated tissue from human heart muscle. The purpose of the study is to determine the maximum feasible dose and safety of CAP-1002 administered by central intravenous infusion (IV line) in PAH patients belonging to one of the subgroups listed above who have been started on PAH-specific medications. CAP-1002 will be used in addition to the participant’s regular treatment regimen.

Condition:

Pulmonary hypertension, chronic obstructive pulmonary disease

Participant Requirements:

  • At least 18 years old
  • Diagnosis of pulmonary hypertension due to chronic obstructive pulmonary disease (PH-COPD); clinical diagnosis of COPD
  • Willing to undergo right heart catheterization during first screening visit if a prior right heart catheterization has not been performed within the past 12 months

Summary:

This study focuses on individuals who have pulmonary hypertension (PH) due to chronic obstructive pulmonary disease (COPD) [PH-COPD] and thus have high blood pressure in their lungs. The purpose of the study is to evaluate the safety and effectiveness of inhaled treprostinil in improving exercise ability in patients with PH-COPD when compared to an inactive solution (placebo). Inhaled treprostinil is a medication that is given by a handheld inhalation device called the Tyvaso Inhalation System. Inhaled treprostinil (brand name Tyvaso) is approved by the U.S. Food and Drug Administration (FDA) for various conditions, but it is not approved by the FDA for the treatment of PH-COPD.

Condition: Pulmonary embolism

Participant Requirements:

  • 18-80 years old
  • Objectively confirmed acute pulmonary embolism
  • Elevated risk of early death/hemodynamic collapse

Summary:

This study focuses on individuals who have been diagnosed with pulmonary embolism (having a blood clot in one or both of the lungs). The purpose of the study is to investigate whether treatment with anticoagulation (blood thinner) medications in combination with the EkoSonic Endovascular device and a dose of a clot-dissolving drug can reduce the risk of death and other serious problems when compared to anticoagulation medication alone.

Condition: Pulmonary embolism

Participant Requirements:

  • Patients diagnosed with PE treated by the Pulmonary Embolism Response Team (PERT)

Summary:

The purpose of this registry is to gather data on patients diagnosed with pulmonary embolism (PE), treated by the Pulmonary Embolism Response Team (PERT) at each site and beyond for epidemiologic, therapeutic, quality assessment and outcomes research.

Condition: Pulmonary arterial hypertension

Participant Requirements:

  • Pulmonary hypertension type 1 with normal right ventricle (RV) function OR
  • Pulmonary hypertension type 1 with RV dysfunction OR
  • Healthy individuals not suspected for a cardiovascular or pulmonary disease

Summary:

The purpose of the study is to evaluate a technique to monitor disease progression or regression in patients with pulmonary arterial hypertension (PAH). Right heart catheterization is currently the standard diagnostic test for PAH patients. This study will evaluate the feasibility of a test based on ultrasound that avoids sending a catheter inside the heart.